Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human Study of K-1728 Administered Alone and in Combination in Participants With Advanced or Metastatic Solid Tumors

NCT07861932 is registered in ClinicalTrials.gov with KymaThera, Inc. as lead sponsor.

NCT NCT07861932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07861932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human Study of K-1728 Administered Alone and in Combination in Participants With Advanced or Metastatic Solid Tumors
Lead sponsor
KymaThera, Inc.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
March 31, 2029
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms, pik3ca gene mutation, solid tumors